5 news items
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
FATE
29 May 24
proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
FATE
3 May 24
proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered master iPSC lines
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
FATE
2 Apr 24
proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
FATE
19 Mar 24
with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
FATE
5 Mar 24
established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC
- Prev
- 1
- Next